Zaiqing Nie
聂再清
Zaiqing Nie is a Chinese AI researcher and biotech entrepreneur who currently serves as a Tsinghua University professor, chief researcher at the Institute for AI Industry Research (AIR), and founder and chief scientist of Shuimu Molecule . His career spans major tech institutions: before joining Tsinghua, he was a principal researcher at Microsoft Research Asia, where he led technical development for Microsoft Academic Search and the natural language understanding platform LUIS; he subsequently joined Alibaba as head of the AI Lab Beijing and chief scientist for Tmall Genie, the company's strategic smart assistant project . At Shuimu Molecule, which grew out of Tsinghua AIR's research environment, Nie leads a "dual-wheel" model combining proprietary drug pipeline development with AI tool empowerment for the biopharma industry . He also heads the large language model for new drug discovery direction under China's 14th Five-Year National Key R&D Program for BTIT integration .
AI-generated — may contain errors, please verify.
Coverage
Exclusive Interview with Professor Nie Zaiqing: Is the Biopharma Version of "AI Lobster" Here? Shuimu Molecular's Dual-Wheel Model of "Proprietary Pipeline + Tool Empowerment" | Tong's Family
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Rooted in Reality, Driven by Innovation, Moving Forward Without Pause | Dalton Venture's 2024 Annual Partners Meeting Successfully Concludes
Pressing forward into the real, advancing toward the new — the resolve to push ahead undimmed.
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
